<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02118051</url>
  </required_header>
  <id_info>
    <org_study_id>POR-ELONVA</org_study_id>
    <secondary_id>2013-002027-42</secondary_id>
    <nct_id>NCT02118051</nct_id>
  </id_info>
  <brief_title>Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response.</brief_title>
  <official_title>Prospective Randomized Study for the Evaluation of Controlled Ovarian Stimulation With Corifollitropin Alpha in Patients With Expected or Poor Ovarian Response in IVF Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigacion Sanitaria La Fe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigacion Sanitaria La Fe</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who have had or are expected to have a poor ovarian response (POR), because they
      meet any of the criteria of Bologna, can benefit from ovarian stimulation with 150 mg of
      alpha Corifollitropin (CFA) (Elonva ®) as single dose for a week, in the cycles of in vitro
      fertilization (IVF).

      In this study aims to demonstrate non-inferiority of the Corifollitropin Alpha (CFA ) versus
      daily administration of Human Menopausal Gonadotropin (hMG) (Menopur ®) during the first
      seven days of ovarian stimulation, in a protocol with gonadotropin-releasing hormone ( GnRH)
      antagonists
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the most significant problems in fertilization treatments is Controlled Ovarian
      Stimulation low responsiveness . The incidence of low ovarian response is estimated at around
      10-25%.The wide range of prevalence reported in the literature can be explained by the lack
      of consensus existed as to the criteria for the low response.

      The ovarian response to gonadotropin stimulation is crucial for successful assisted
      reproduction techniques .Cycles with low rates response was obtained and increased
      cancellation rate and worst pregnancy rates .

      Different criteria for the definition of low response, different tests to assess ovarian
      reserve and different threshold values for each has been used.

      In 2010 a group of experts from the ESHRE ,achieved consensus on the criteria for low ovarian
      response to homogenize the study groups and reach meaningful conclusions, are known as &quot;The
      Bologna criteria&quot; ,they defined the &quot;Poor Ovarian Response&quot; (POR).

      There is not sufficient to recommend most of the proposed treatments to improve pregnancy
      rates in poor responders evidence.

      Taking into account the profile of equivalence and safety of CFA (Corifollitropin Alpha ,
      active of ELONVA ® ) , different studies had been concluded that CFA can be an alternative to
      daily injections of recombinant follicle stimulating hormone ( rFSH) in normal responders
      patients in vitro fertilization cycle with ovarian stimulation.But more research is needed to
      determine whether long-acting recombinant follicle stimulating hormone ( rFSH) is safe and
      effective for use in women with low and high response.

      The ovarian controlled stimulation with Alpha Corifollitropin produces significantly more
      oocytes compared to recombinant follicle stimulating hormone (r FSH ) administrated daily in
      normal responders patients, For this reason , the use of Alpha Corifollitropin may be
      beneficial in patients with poor response which the number of oocytes retrieved is crucial
      for successful treatment

      There have been two studies in which the results are compared after ovarian stimulation with
      daily rFSH vs CFA . In both shows , retrospectively and prospectively , the CFA seems to be
      at least as effective as hMG recombinant follicle stimulating hormone ( rFSH) daily.

      There are scientific publications showing that the association of luteinizing hormone ( LH)
      to recombinant follicle stimulating hormone ( rFSH) can improve embryos quality and achieved
      better pregnancy rate . The pregnancy rate was not statistically significant , in normal
      responders patients.

      Recently reported the beneficial effect in POR patients treated with CFA and hMG.

      The IVF treatment is known to affects the physical and mental condition in patients with
      infertility , being the excess emotional stress one of the most important reasons for
      discontinuation of treatment.

      The ovarian stimulation with CFA simplifies treatment , reducing the administration of
      multiple daily injections ,and may reduce the emotional burden on patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of evolutionary gestation in each cycle</measure>
    <time_frame>20 week of gestation</time_frame>
    <description>Evolutionary pregnancy has been defined as gestation of at least 1 fetus reaches 20 weeks of gestation diagnosed by normal ultrasound or confirmed by live birth</description>
  </primary_outcome>
  <primary_outcome>
    <measure>oocytes (MII) rate by patient</measure>
    <time_frame>participants will be followed for the duration of the cycle,an expected average of 8-16 days.</time_frame>
    <description>When follicular puncture occurs, we value the number of punctured follicles, total oocytes and MII oocytes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>participants will be followed for the duration of the cycle,an expected average of 16 days.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">234</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>CFA , hMG,Ganirelix,choriogonadotropin alfa,progesterone.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Corifollitropin Alfa (CFA) 150 ug from the 2nd day of the cycle for 7 days. hMG 300 IU/24h, if required from the 8th day of the Controlled Ovarian Stimulation , until the day human chorionic gonadotropin ( hCG.) Ganirelix 0.25 mg,Dose: 250μg/24h since the day observe a follicle&gt; 14mm. Recombinant choriogonadotropin alfa,Dose: 6,500 IU, pods, when follicles&gt; 17 mm are observed.
Micronized natural progesterone. Route of administration: vaginal. Dose: 400mg/24, from embryo transfer until the day of b-hCG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hMG ,Ganirelix,choriogonadotropin alfa,progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Human Menopausal Gonadotropin (hMG). Dose: 300 IU/24h from the 2nd day of the cycle throughout the stimulation.
Ganirelix 0.25 mg,Dose: 250μg/24h since the day observe a follicle&gt; 14mm. Recombinant choriogonadotropin alfa,Dose: 6,500 IU, pods, when follicles&gt; 17 mm are observed.
Micronized natural progesterone. Route of administration: vaginal. Dose: 400mg/24, from embryo transfer until the day of b-hCG.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganirelix 0.25 mg.</intervention_name>
    <description>Ganirelix 0.25 mg. Route of administration: Subcutaneous use. Dose: 250μg/24h since the day observe a follicle&gt; 14mm.</description>
    <arm_group_label>CFA , hMG,Ganirelix,choriogonadotropin alfa,progesterone.</arm_group_label>
    <arm_group_label>hMG ,Ganirelix,choriogonadotropin alfa,progesterone</arm_group_label>
    <other_name>ORGALUTRAN®.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant choriogonadotropin alfa</intervention_name>
    <description>Recombinant choriogonadotropin alfa. Route of administration: Subcutaneous use. Dose: 6,500 IU, pods, when follicles&gt; 17 mm are observed</description>
    <arm_group_label>CFA , hMG,Ganirelix,choriogonadotropin alfa,progesterone.</arm_group_label>
    <arm_group_label>hMG ,Ganirelix,choriogonadotropin alfa,progesterone</arm_group_label>
    <other_name>OVITRELLE®.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micronized natural progesterone.</intervention_name>
    <description>Micronized natural progesterone. Route of administration: vaginal . Dose: 400mg/24, from embryo transfer until the day of b-hCG.</description>
    <arm_group_label>CFA , hMG,Ganirelix,choriogonadotropin alfa,progesterone.</arm_group_label>
    <arm_group_label>hMG ,Ganirelix,choriogonadotropin alfa,progesterone</arm_group_label>
    <other_name>PROGEFFIK®.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. - Age ≥ 18 years old.

          2. - Signed informed consent to perform IVF and participation in this study.

          3. - Due to characteristics of our center not perform treatments in patients

               -  40 years old ,and being one of the Bologna criteria that we will not be able to
                  consider ,we decided to include patients affected subsidiary infertility
                  treatment by IVF or intracytoplasmatic sperm injection (ICSI), present one of the
                  following factors

                    1. Have a history of surgical or medical treatment as a risk factor for POR.

                    2. Patients witch had have a poor ovarian response in response to the ovarian
                       controlled stimulation (previous cycle after conventional stimulation with ≤
                       3 oocytes)

                    3. Patients with ovarian reserve test anti-mullerian hormone(AMH ) &lt;1.1 ng / ml
                       (&lt;8 pM) or antral follicle count (AFC)&lt;7

        Exclusion Criteria:

          1. -Anovulation.

          2. -Patient with tubal factor, untreated

          3. -Patient with uterine pathology untreated

          4. - Couples with severe male factor, fresh count &lt;5 million / ml, and azoospermia in
             which the patient's sperm, epididymal or testicular is used
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roser Taroncher</last_name>
    <role>Principal Investigator</role>
    <affiliation>La Fe University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Human Reproduction Unit of the La Fe University and Politechnic Hospital</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Cousineau TM, Domar AD. Psychological impact of infertility. Best Pract Res Clin Obstet Gynaecol. 2007 Apr;21(2):293-308. Epub 2007 Jan 22. Review.</citation>
    <PMID>17241818</PMID>
  </reference>
  <reference>
    <citation>Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC; ENGAGE Investigators. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod. 2009 Dec;24(12):3063-72. doi: 10.1093/humrep/dep291. Epub 2009 Aug 14. Erratum in: Hum Reprod. 2014 May;29(5):1116-20.</citation>
    <PMID>19684043</PMID>
  </reference>
  <reference>
    <citation>Devroey P, Fauser BC, Platteau P, Beckers NG, Dhont M, Mannaerts BM. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab. 2004 May;89(5):2062-70.</citation>
    <PMID>15126522</PMID>
  </reference>
  <reference>
    <citation>Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011 Jul;26(7):1616-24. doi: 10.1093/humrep/der092. Epub 2011 Apr 19.</citation>
    <PMID>21505041</PMID>
  </reference>
  <reference>
    <citation>Keay SD, Liversedge NH, Mathur RS, Jenkins JM. Assisted conception following poor ovarian response to gonadotrophin stimulation. Br J Obstet Gynaecol. 1997 May;104(5):521-7. Review.</citation>
    <PMID>9166190</PMID>
  </reference>
  <reference>
    <citation>Kim CH, Jeon GH, Cheon YP, Jeon I, Kim SH, Chae HD, Kang BM. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low-dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertil Steril. 2009 Nov;92(5):1758-60. doi: 10.1016/j.fertnstert.2009.05.013. Epub 2009 Jun 12.</citation>
    <PMID>19523618</PMID>
  </reference>
  <reference>
    <citation>Kyrou Kolibianakis EM, Masouridou S, Chatzimeletiou K, Mitsoli A, Tarlatzis BC. Is corifollitropin alfa beneficial in poor responders undergoing IVF?. O-285. Congreso ESHRE 2012.</citation>
  </reference>
  <reference>
    <citation>Kyrou D, Kolibianakis EM, Venetis CA, Papanikolaou EG, Bontis J, Tarlatzis BC. How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil Steril. 2009 Mar;91(3):749-66. doi: 10.1016/j.fertnstert.2007.12.077. Epub 2008 Jul 21. Review.</citation>
    <PMID>18639875</PMID>
  </reference>
  <reference>
    <citation>Mahmoud Youssef MA, van Wely M, Aboulfoutouh I, El-Khyat W, van der Veen F, Al-Inany H. Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis. Fertil Steril. 2012 Apr;97(4):876-85. doi: 10.1016/j.fertnstert.2012.01.092. Epub 2012 Jan 23. Review. Erratum in: Fertil Steril. 2012 Jun;97(6):1479.</citation>
    <PMID>22277766</PMID>
  </reference>
  <reference>
    <citation>Pandian Z, McTavish AR, Aucott L, Hamilton MP, Bhattacharya S. Interventions for 'poor responders' to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF). Cochrane Database Syst Rev. 2010 Jan 20;(1):CD004379. doi: 10.1002/14651858.CD004379.pub3. Review.</citation>
    <PMID>20091563</PMID>
  </reference>
  <reference>
    <citation>Pellicer A, Lightman A, Diamond MP, Russell JB, DeCherney AH. Outcome of in vitro fertilization in women with low response to ovarian stimulation. Fertil Steril. 1987 May;47(5):812-5.</citation>
    <PMID>3106105</PMID>
  </reference>
  <reference>
    <citation>Pellicer A, Ardiles G, Neuspiller F, Remohí J, Simón C, Bonilla-Musoles F. Evaluation of the ovarian reserve in young low responders with normal basal levels of follicle-stimulating hormone using three-dimensional ultrasonography. Fertil Steril. 1998 Oct;70(4):671-5.</citation>
    <PMID>9797096</PMID>
  </reference>
  <reference>
    <citation>Polyzos NP, De Vos M, Corona R, Vloeberghs V, Ortega-Hrepich C, Stoop D, Tournaye H. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study. Hum Reprod. 2013 May;28(5):1254-60. doi: 10.1093/humrep/det045. Epub 2013 Feb 26.</citation>
    <PMID>23442756</PMID>
  </reference>
  <reference>
    <citation>Polyzos NP, Devos M, Humaidan P, Stoop D, Ortega-Hrepich C, Devroey P, Tournaye H. Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: an observational pilot study. Fertil Steril. 2013 Feb;99(2):422-6. doi: 10.1016/j.fertnstert.2012.09.043. Epub 2012 Oct 16.</citation>
    <PMID>23084565</PMID>
  </reference>
  <reference>
    <citation>Pouwer AW, Farquhar C, Kremer JA. Long-acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database Syst Rev. 2012 Jun 13;(6):CD009577. doi: 10.1002/14651858.CD009577.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;(7):CD009577.</citation>
    <PMID>22696386</PMID>
  </reference>
  <reference>
    <citation>Requena A, Landeras JL, Martínez-Navarro L, Calatayud C, Sánchez F, Maldonado V, Muñoz M, Fernández M, González A, López S, López R, Pacheco A, Calderón G, Martínez V. Could the addition of hp-hMG and GnRH antagonists modulate the response in IVF-ICSI cycles? Hum Fertil (Camb). 2010 Mar;13(1):41-9. doi: 10.3109/14647270903586356.</citation>
    <PMID>20384441</PMID>
  </reference>
  <reference>
    <citation>Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J. Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum Reprod Update. 2003 Jan-Feb;9(1):61-76. Review.</citation>
    <PMID>12638782</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2014</study_first_submitted>
  <study_first_submitted_qc>April 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infertility</keyword>
  <keyword>IVF</keyword>
  <keyword>Corifollitropin Alfa treatment</keyword>
  <keyword>Ovarian stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Ganirelix</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

